<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="30314">Lipoic acid</z:chebi> (LA), which has significant <z:chebi fb="11" ids="22586">antioxidant</z:chebi> properties, may also function as a potent neuroprotectant </plain></SENT>
<SENT sid="2" pm="."><plain>The synthetic compounds INV-155, INV-157, INV-159, and INV-161 are physiochemical combinations of <z:chebi fb="0" ids="30314">lipoic acid</z:chebi> and <z:chebi fb="0" ids="3380">captopril</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>We sought to determine if these compounds have neuroprotective potential following middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) in rats </plain></SENT>
<SENT sid="4" pm="."><plain>Methods </plain></SENT>
<SENT sid="5" pm="."><plain>Male Sprague-Dawley rats were injected intravenously with <z:chebi fb="0" ids="3380">captopril</z:chebi> (1-50 mg/kg) 30 minutes prior to MCAO </plain></SENT>
<SENT sid="6" pm="."><plain>Blood pressure, heart rate, baroreceptor reflex sensitivity, and <z:mpath ids='MPATH_124'>infarct</z:mpath> size were measured </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, dose response effect on <z:mpath ids='MPATH_124'>infarct</z:mpath> size and cardiovascular parameters was determined using INV-155, INV-157, INV-159, and INV-161 and compared to <z:chebi fb="0" ids="3380">captopril</z:chebi> and LA </plain></SENT>
<SENT sid="8" pm="."><plain>Results </plain></SENT>
<SENT sid="9" pm="."><plain>Pretreatment with <z:chebi fb="0" ids="3380">captopril</z:chebi> and LA at <z:hpo ids='HP_0000001'>all</z:hpo> doses tested was neuroprotective </plain></SENT>
<SENT sid="10" pm="."><plain>The compounds INV-159 (0.5-10 mg/kg) and INV-161 (1-10 mg/kg) produced a significant,dose-dependent decrease in <z:mpath ids='MPATH_124'>infarct</z:mpath> size </plain></SENT>
<SENT sid="11" pm="."><plain>In contrast, INV-155 and INV-157 had no effect on <z:mpath ids='MPATH_124'>infarct</z:mpath> size </plain></SENT>
<SENT sid="12" pm="."><plain>Conclusions </plain></SENT>
<SENT sid="13" pm="."><plain>Combined pretreatment with <z:chebi fb="0" ids="3380">captopril</z:chebi> potentiated the neuroprotective benefit observed following LA alone </plain></SENT>
<SENT sid="14" pm="."><plain>Both INV-159 and INV-161 were also neuroprotective </plain></SENT>
<SENT sid="15" pm="."><plain>These results suggest that patients taking combinations of <z:chebi fb="0" ids="3380">captopril</z:chebi> and LA, either as combination therapy or in the form of INV-159 or INV-161, may also benefit from significant protection against <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> </plain></SENT>
</text></document>